Skip to content
Open access

Association Between Plasma N-Terminal Tau, Cognitive Decline, and Neurodegeneration in the ADNI Cohort.

Nov 2026 · Neurology · Vol 107 10, pp. e218564 · 0 citations · 28 references
Medicine

TL;DR

Plasma NT1 may be useful in assessing amyloid-dependent cognitive decline and neurodegeneration and may be useful in assessing amyloid-dependent cognitive decline and neurodegeneration.

Abstract

Background

AND

Objectives

Blood-based biomarkers offer a cost-effective, minimally invasive alternative to neuroimaging and CSF biomarkers. Newly developed fluid biomarkers, including the N-terminal tau fragment (NT1), show promise for identifying individuals at risk for Alzheimer disease (AD) and for monitoring disease progression. Here, we determine whether NT1 levels are associated with key clinical and biomarker measures in a large, well-characterized cohort.

Methods

Participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort with available plasma NT1, β-amyloid (Aβ)-PET, MRI, and clinical measures (Clinical Dementia Rating) were included in this observational study. NT1 was measured using the Quanterix Simoa HD-X platform. PET, MRI, clinical, and other plasma measures were obtained using established ADNI procedures. A subset also had NULISA-based plasma measures of amyloid and tau and tau-PET assessed. Linear regression and linear mixed-effects models were used to assess cross-sectional and longitudinal associations between NT1 and clinical or biomarker measures, adjusting for relevant covariates. Multivariable-adjusted Cox regression was performed to evaluate the association between baseline NT1 levels and risk of clinically diagnosed mild cognitive impairment (MCI) or AD. Mediation analysis was conducted to examine whether hippocampal atrophy mediates the relationship between NT1 and memory decline. Spearman correlations were used to examine continuous relationships between plasma NT1 and continuous fluid and neuroimaging markers.

Results

A total of 755 participants (mean age: 72.9 [7.0], female: 375 [50%]) were included in the study. Plasma NT1 levels were elevated in MCI/AD individuals (BMCI/AD [SE] = 0.09 [0.022], p = 1.98 × 10-4) and were cross-sectionally associated with worse memory performance (B [SE] = -0.25 [0.09], p = 0.005). Aβ moderated the association between elevated NT1 and greater cognitive decline across multiple domains (memory: B [SE] = -0.17 [0.074], p = 0.022; executive function: B [SE] = -0.24 [0.082], p = 0.004; language: B [SE] = -0.21 [0.075], p = 0.006). NT1 levels were negatively associated with hippocampal volume (B [SE] = -264.49 [125.99], p = 0.036) and predicted longitudinal atrophy (B [SE] = -42.00 [16.90], p = 0.013). Accelerated hippocampal atrophy largely mediated the association between higher baseline NT1 level and greater memory decline (B [95% CI]indirect effect = -0.082 [-0.135 to -0.03], p = 0.003, B [95% CI]proportion mediated = 70.1% [32.6%-155.3%], p = 0.004). Higher NT1 levels were associated with higher levels of plasma biomarkers, including NULISA-based brain-derived (BD) plasma pTau (BD-pTau181, BD-pTau217, BD-pTau231: p's < 5.01 × 10-6) and Simoa-Based pTau181 (p < 4.51 × 10-15) and neurofilament light chain (p < 5.34 × 10-7).

Discussion

Plasma NT1 may be useful in assessing amyloid-dependent cognitive decline and neurodegeneration.

Read PDF

Similar papers

Open access Oct 2026

Blood-based biomarkers across the Alzheimer's disease continuum in older Korean population

Background: Plasma phosphorylated tau 217 (pTau217) is a robust biomarker of Alzheimer's disease (AD) pathology. However, whether a single biomarker can adequately capture both clinical diagnosis and disease progression remains unclear. We investigated the complementary roles of plasma AD biomarkers and routinely measu...

S. Kang, Y. Y. Choi, M. Kim et al. · 0 citations
Open access Oct 2026

Plasma biomarkers and incident clinical stage progression in the specialized memory clinic: a longitudinal study

INTRODUCTION: The utility of blood-based Alzheimer's disease (AD) biomarkers in predicting clinical trajectories remains uncertain. METHODS: We assessed the diagnostic and prognostic performance of p-tau181, p-tau217, GFAP, and NfL in a large memory-clinic cohort (n=3,645) with comprehensive baseline clinical evaluatio...

Xue-Mei Zeng, Nicholas Heaton, Rebecca A. Deek et al. · 0 citations
Open access Nov 2026

Plasma p-tau217 as a biomarker mapping cognitive impairment in Alzheimer's disease.

OBJECTIVE Plasma p-tau217 is a well-established biomarker of Alzheimer disease (AD) pathology, but its relationship with cognitive status and longitudinal cognitive change remains less well characterized. We investigated the clinical relevance of plasma p-tau217 as a blood-based biological correlate of cognitive status...

Ming-Qing Wei, Jun-Lei Zhang, Xin-Ke Liu et al. · 0 citations
Open access Dec 2026

Plasma P-Tau217 as a Prognostic, Monitoring, and Risk-Stratification Biomarker of Clinical Progression in Lewy Body Disease.

BACKGROUND AND OBJECTIVES Although plasma phosphorylated tau-217 (pTau217) detects co-occurring Alzheimer disease (AD) neuropathologic change in Lewy body disease (LBD), relationships with long-term clinical outcomes remain unclear. Our aim was to evaluate plasma pTau217 as a prognostic, risk-stratification, and monito...

S. Lorkiewicz, C. Abdelnour, M. Bolen et al. · 0 citations
Open access Dec 2025

Developing Topics.

BACKGROUND Demonstrating the specificity of plasma biomarkers to AD-related neurodegeneration would add support to their prognostic and diagnostic clinical use. METHOD Participants from the Baltimore Longitudinal Study of Aging were cognitively unimpaired at the time of their plasma Aβ42/Aβ40, GFAP, NfL (Quanterix Ne...

Murat Bilgel, Ishaan Shah, Jasmine M. Cooper et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.